Neoplasms, Neuroepithelial  >>  crenolanib (ARO-002)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
crenolanib (ARO-002) / AROG
NCT01229644: Study of Crenolanib, a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas

Terminated
2
10
US
Crenolanib (CP-868,596), Crenolanib Besylate
Arog Pharmaceuticals, Inc.
Glioma
06/12
12/12

Download Options